BFS
DFTX

Bard Financial Services’s Definium Therapeutics DFTX Stock Holding History

Bard Financial Services’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$21K – 302
2021
Q4 		$21K Buy
+1,000
New +$31.9K ﹤0.01% 283

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Bard Financial Services's DFTX Position: Q1 2022 in Review

Bard Financial Services sold out of Definium Therapeutics (DFTX) in Q1 2022, closing a stake of 1,000 shares — an estimated $21K sold.

Bard Financial Services first reported a position in DFTX in Q4 2021 and held it in 1 quarter. The position peaked at $21K in Q4 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q1 2022.

  • Bard Financial Services reported no remaining Definium Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Bard Financial Services sold 1,000 Definium Therapeutics shares in Q1 2022, an estimated $21K.
  • Bard Financial Services first reported a position in Definium Therapeutics in Q4 2021 and held it in 1 quarter.
  • Bard Financial Services's Definium Therapeutics position peaked at $21K in Q4 2021.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2022.

Based on Bard Financial Services's 13F filing for Q1 2022, filed 13 Apr 2022.